DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Levaquin (Levofloxacin) - Published Studies

 
 



Levaquin Related Published Studies

Well-designed clinical trials related to Levaquin (Levofloxacin)

Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. [2014]

Efficacy of levofloxacin in the treatment of BK viremia: a multicenter, double-blinded, randomized, placebo-controlled trial. [2014]

Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia. [2013]

Prulifloxacin versus levofloxacin in the treatment of respiratory and urinary tract infections: a multicentre, double-blind, randomized controlled clinical trial. [2012]

Second-line levofloxacin-based triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer. [2011.08]

Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. [2011.06.01]

Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial. [2011.06]

Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. [2011.06]

Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial. [2011.02.02]

Bioequivalence study of levofloxacin tablets in healthy Indian volunteers using HPLC. [2011]

[A multi-center, randomized, controlled, double blind and double dummy clinical trial of antofloxacin hydrochloride tablet versus levofloxacin tablet for the treatment of acute bacterial infections]. [Article in Chinese] [2011]

Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. [2011]

Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial. [2011]

Aqueous and vitreous penetration of linezolid and levofloxacin after oral administration. [2010.12]

Short-term comparative study of the effects of preserved and unpreserved topical levofloxacin on the human ocular surface. [2010.12]

Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults. [2010.11]

Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. [2010.11]

Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia. [2010.10]

A randomized prospective study of oral levofloxacin vs intravenous flomoxef prophylaxis in postoperative infection after endoscopic sinus surgery. [2010.09]

Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study. [2010.08]

Permeability and concentration of levofloxacin in epithelial lining fluid in patients with lower respiratory tract infections. [2010.08]

Safety and efficacy of levofloxacin 750 mg for 2 weeks or 3 weeks compared with levofloxacin 500 mg for 4 weeks in treating chronic bacterial prostatitis. [2010.06]

Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design. [2010.05]

Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. [2010.05]

Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia. [2010.04]

Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers. [2010.04]

Tear concentration and safety of levofloxacin ophthalmic solution 1.5% compared with ofloxacin ophthalmic solution 0.3% after topical administration in healthy adult volunteers. [2010.03]

Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia. [2010.03]

[Levofloxacin-based triple therapy for first-line Helicobacter pylori eradication treatment: a multi-central, randomized, controlled clinical study] [2010.01.12]

Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children. [2010.01]

Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia. [2010]

Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia. [2010]

Safety and efficacy of levofloxacin 750 mg for 2 weeks or 3 weeks compared with levofloxacin 500 mg for 4 weeks in treating chronic bacterial prostatitis. [2010]

Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children. [2010]

Levofloxacin prophylaxis to prevent bacterial infection in chemotherapy-induced neutropenia in acute leukemia. [2009.12]

[Human aqueous humor levels of levofloxacin 0.5%, gatifloxacin 0.3% and levofloxacin 0.3% ophthalmic solution after topical dosing.] [2009.11]

Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China. [2009.10]

Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. [2009.09.09]

Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. [2009.09]

Bioavailability of two oral formulations of a single dose of levofloxacin 500 mg: an open-label, randomized, two-period crossover comparison in healthy Mexican volunteers. [2009.08]

A prospective study determining the efficacy of topical 0.5% levofloxacin on bacterial flora of patients with chronic blepharoconjunctivitis. [2009.07]

Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication. [2009.07]

Levofloxacin versus azithromycin on the oropharyngeal carriage and selection of antibacterial- resistant streptococci in the microflora of healthy adults. [2009.06]

Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. [2009.05]

Comparative bioavailability of two oral formulations of levofloxacin in healthy Mexican volunteers. [2009.04]

Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. [2009.04]

Increased anterior chamber penetration of topical levofloxacin 0.5% after pulsed dosing in cataract patients. [2009.03]

Clinical and microbiological efficacy of levofloxacin administered three times a day for the treatment of bacterial conjunctivitis. [2009.01]

Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. [2009.01]

Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience. [2008.10]

Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. [2008.07]

Antibiotic prophylaxis for transrectal prostate biopsy: a prospective randomized study of tosufloxacin versus levofloxacin. [2008.07]

A randomized comparative study of levofloxacin versus amoxicillin/clavulanate for treatment of infants and young children with recurrent or persistent acute otitis media. [2008.06]

A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial. [2008.05]

[Efficacy of Levofloxacin-based Triple Therapy as Second-lineHelicobacter pylori Eradication.] [2008.05]

Ocular penetration of levofloxacin, ofloxacin and ciprofloxacin in eyes with functioning filtering blebs: investigator masked, randomised clinical trial. [2008.03]

Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. [2008.03]

A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. [2008.01]

Is levofloxacin necessary to prevent postoperative infections of auricular second-intention wounds? [2008.01]

A prospective randomized study to determine the efficacy of preoperative topical levofloxacin in reducing conjunctival bacterial flora. [2008.01]

[Yiqigushen capsule combined with levofloxacin highly effective for type III A prostatitis] [2008.01]

Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination. [2008]

The ocular penetration of levofloxacin 1.5% and gatifloxacin 0.3% ophthalmic solutions in subjects undergoing corneal transplant surgery. [2007.12]

A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. [2007.11]

Clinical trial: levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infection. [2007.10.01]

Comparative Study of Levofloxacin in the Treatment of Children With Community-Acquired Pneumonia. [2007.10]

Prospective randomized comparison of 1-day versus 3-day application of topical levofloxacin in eliminating conjunctival flora. [2007.09]

Helicobacter pylori eradication with either quadruple regimen with lactoferrin or levofloxacin-based triple therapy: a multicentre study. [2007.09]

Levofloxacin-Containing Triple Therapy to Eradicate the Persistent H. pylori after a Failed Conventional Triple Therapy. [2007.08]

Azithromycin and loperamide are comparable to levofloxacin and loperamide for the treatment of traveler's diarrhea in United States military personnel in Turkey. [2007.08]

Levofloxacin 500 mg once daily versus cefuroxime 250 mg twice daily in patients with acute exacerbations of chronic obstructive bronchitis: clinical efficacy and exacerbation-free interval. [2007.07]

An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia. [2007.07]

Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial. [2007.06]

Levofloxacin vs. ciprofloxacin plus phenethicillin for the prevention of bacterial infections in patients with haematological malignancies. [2007.05]

Aqueous and vitreous penetration of levofloxacin after topical and/or oral administration. [2007.05]

[Longqingpian combined with levofloxacin highly effective for type IIIA prostatitis] [2007.04]

Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. [2007.02.01]

Levofloxacin treatment in patients with rheumatoid arthritis receiving methotrexate. [2007.02]

Levofloxacin- vs. Ranitidine Bismuth Citrate-Containing Therapy After H. pylori Treatment Failure. [2007.02]

Open-label, randomized comparison trial of long-term outcomes of levofloxacin versus standard antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. [2007.01]

Time of administration of a single dose of oral levofloxacin and its effect in infectious complications from transrectal prostate biopsy. [2007]

Penetration of topically applied levofloxacin 0.5% and ofloxacin 0.3% into the vitreous of the non-inflamed human eye. [2006.12]

Urinary bactericidal activity of extended-release ciprofloxacin (1,000 milligrams) versus levofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. [2006.11]

Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. [2006.09]

Early discharge of hospitalised patients with community-acquired urosepsis when treated with levofloxacin in sequential therapy. [2006.09]

Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort. [2006.09]

Levofloxacin 750 mg QD for five days versus amoxicillin/clavulanate 875 mg/125 mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis: a post hoc analysis of data from severely ill patients. [2006.08]

Altered steady state pharmacokinetics of levofloxacin in adult cystic fibrosis patients receiving calcium carbonate. [2006.08]

Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole. [2006.07]

Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. [2006.06]

Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. [2006.02.01]

7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity. [2006.02]

Levofloxacin does not decrease mortality in Staphylococcus aureus bacteraemia when added to the standard treatment: a prospective and randomized clinical trial of 381 patients. [2006.02]

A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication. [2006.01.15]

Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. [2006.01.01]

[Levofloxacin-Azithromycin Combined Triple Therapy for Helicobacter pylori Eradication.] [2006.01]

A trial of high-dose, short-course levofloxacin for the treatment of acute bacterial sinusitis. [2006.01]

Pharmacokinetics of ciprofloxacin XR (1000mg) versus levofloxacin (500mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose. [2006.01]

A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. [2005.11]

A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: results from the CAP-IN trial. [2005.11]

Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. [2005.11]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014